Zencurix Introduces Digital PCR-Based Companion Diagnostic Products at American Society of Molecular Pathology Conference

Cancer diagnosis specialist GenCurix announced on the 28th that it participated in the American Association for Molecular Pathology (AMP 2024) and showcased its digital PCR-based cancer diagnostic technology and companion diagnostic products.

GenCurix introduced the DropFlex EGFR Mutation Test v2, which can detect mutations essential for targeted therapy in non-small cell lung cancer patients. It accurately identifies mutations related to third-generation EGFR TKIs such as Osimertinib and Lazertinib. By monitoring ctDNA in the blood, it can evaluate treatment response and risk of recurrence. The DropFlex EGFR Mutation Test v2 received significant attention for its potential use in assessing the effectiveness of anticancer drug treatment and monitoring recurrence.

Various solutions were also presented, including the DropFlex Lung Cancer Panel, which analyzes 11 major genes of non-small cell lung cancer, and the DropFlex ESR1 Mutation Test, which detects ESR1 mutations related to endocrine therapy response in breast cancer through blood samples.

Jung Jong-seok, Head of the Global Business Division, said, "We were able to introduce GenCurix’s technology and products to molecular pathology experts in North America and discuss cooperation plans with several North American diagnostic companies for market entry."